OCGN - Ocugen, Inc.
Ocugen, Inc.
263 Great Valley Parkway
Suite 160
Malvern, PA 19355
United States
484 328 4701
https://www.ocugen.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 84
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Shankar Musunuri M.B.A., MBA, Ph.D. | Co-Founder, Chairman & CEO | 1,2M | 1,26M | 1964 |
| Dr. Uday B. Kompella Ph.D. | Co-founder & Independent Director | 56,72k | N/A | 1967 |
| Mr. Quan Anh Vu | CFO, Chief Bus. Officer & Principal Accounting Officer | N/A | N/A | 1973 |
| Dr. Arun Upadhyay Ph.D. | Chief Scientific Officer and Head of Research, Devel. & Medical | N/A | N/A | 1982 |
| Ms. Tiffany J. Hamilton M.B.A. | Head of Corp. Communications | N/A | N/A | N/A |
| Ms. Zara Gaudioso | AVP, Head of HR & Chief of Staff | N/A | N/A | N/A |
| Mr. Michael Shine M.B.A. | Sr. VP of Commercial | N/A | N/A | N/A |
| Ms. Jyothy Pillai M.S. | Head of Regulatory & Quality | N/A | N/A | N/A |
| Dr. Huma Qamar CMI, M.D., M.P.H. | Head of Clinical Devel. & Medical Affairs | N/A | N/A | N/A |
Descripción
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410 and OCU410ST for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. It has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
Gobierno corporativo
El ISS Governance QualityScore de Ocugen, Inc., a día 30 de mayo de 2023, es 7. Las puntuaciones base son Auditoría: 7; Tablero: 7; Derechos de los accionistas: 8; Compensación: 6.
